These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 17211914)

  • 21. Molecular motions in HIV-1 gp120 mutants reveal their preferences for different conformations.
    Liu SQ; Liu CQ; Fu YX
    J Mol Graph Model; 2007 Jul; 26(1):306-18. PubMed ID: 17227719
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Identification of putative, stable binding regions through flexibility analysis of HIV-1 gp120.
    Tan H; Rader AJ
    Proteins; 2009 Mar; 74(4):881-94. PubMed ID: 18704932
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Spatial structure model of the CD4 receptor-binding site of the HIV envelope protein gp120.
    Andrianov AM
    J Biomol Struct Dyn; 1998 Jun; 15(6):1101-13. PubMed ID: 9669555
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Molecular dynamics study of the proposed beta-hairpin form of the switch domain from HIV1 gp120 alone and complexed with an inhibitor of CD4 binding.
    Graf von Stosch A; von der Lieth CW; Reed J
    Proteins; 1999 Feb; 34(2):197-205. PubMed ID: 10022355
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Human immunodeficiency virus: refolding the envelope.
    Kwong PD
    Nature; 2005 Feb; 433(7028):815-6. PubMed ID: 15729327
    [No Abstract]   [Full Text] [Related]  

  • 26. A common pharmacophoric footprint for AIDS vaccine design.
    Pisterer C; Mihailescu D; Smith JC; Reed J
    J Med Chem; 2004 Jul; 47(15):3723-9. PubMed ID: 15239651
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Design, synthesis and evaluation of potential inhibitors of HIV gp120-CD4 interactions.
    Boussard C; Klimkait T; Mahmood N; Pritchard M; Gilbert IH
    Bioorg Med Chem Lett; 2004 May; 14(10):2673-6. PubMed ID: 15109676
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rational conversion of noncontinuous active region in proteins into a small orally bioavailable macrocyclic drug-like molecule: the HIV-1 CD4:gp120 paradigm.
    Hurevich M; Swed A; Joubran S; Cohen S; Freeman NS; Britan-Rosich E; Briant-Longuet L; Bardy M; Devaux C; Kotler M; Hoffman A; Gilon C
    Bioorg Med Chem; 2010 Aug; 18(15):5754-61. PubMed ID: 20619663
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Structural studies of human HIV-1 V3 antibodies.
    Stanfield RL; Wilson IA
    Hum Antibodies; 2005; 14(3-4):73-80. PubMed ID: 16720977
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacological descriptors related to the binding of Gp120 to CD4 corresponding to 60 representative HIV-1 strains.
    Calborean O; Mernea M; Avram S; Mihailescu DF
    J Enzyme Inhib Med Chem; 2013 Oct; 28(5):1015-25. PubMed ID: 22957718
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Structure-based design of P3 moieties in the peptide mimetic factor VIIa inhibitor.
    Kadono S; Sakamoto A; Kikuchi Y; Oh-eda M; Yabuta N; Yoshihashi K; Kitazawa T; Suzuki T; Koga T; Hattori K; Shiraishi T; Haramura M; Kodama H; Ono Y; Esaki T; Sato H; Watanabe Y; Itoh S; Ohta M; Kozono T
    Biochem Biophys Res Commun; 2005 Feb; 327(2):589-96. PubMed ID: 15629154
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Scorpion-toxin mimics of CD4 in complex with human immunodeficiency virus gp120 crystal structures, molecular mimicry, and neutralization breadth.
    Huang CC; Stricher F; Martin L; Decker JM; Majeed S; Barthe P; Hendrickson WA; Robinson J; Roumestand C; Sodroski J; Wyatt R; Shaw GM; Vita C; Kwong PD
    Structure; 2005 May; 13(5):755-68. PubMed ID: 15893666
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Beta-hairpin peptidomimetics: design, structures and biological activities.
    Robinson JA
    Acc Chem Res; 2008 Oct; 41(10):1278-88. PubMed ID: 18412373
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Role of the HIV gp120 conserved domain 5 in processing and viral entry.
    Sen J; Jacobs A; Caffrey M
    Biochemistry; 2008 Jul; 47(30):7788-95. PubMed ID: 18597484
    [TBL] [Abstract][Full Text] [Related]  

  • 35. STD NMR study of the interactions between antibody 2G12 and synthetic oligomannosides that mimic selected branches of gp120 glycans.
    Enríquez-Navas PM; Chiodo F; Marradi M; Angulo J; Penadés S
    Chembiochem; 2012 Jun; 13(9):1357-65. PubMed ID: 22628288
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of chronic alcohol drinking on receptor-binding, internalization, and degradation of human immunodeficiency virus 1 envelope protein gp120 in hepatocytes.
    Singh AK; Jiang Y; Gupta S
    Alcohol; 2007 Dec; 41(8):591-606. PubMed ID: 17980997
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Probing of CD4 binding pocket of HIV-1 gp120 glycoprotein using unnatural phenylalanine analogues.
    Yu X; Talukder P; Bhattacharya C; Fahmi NE; Lines JA; Dedkova LM; LaBaer J; Hecht SM; Chen S
    Bioorg Med Chem Lett; 2014 Dec; 24(24):5699-5703. PubMed ID: 25453804
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Peptides as protein binding site mimetics.
    Eichler J
    Curr Opin Chem Biol; 2008 Dec; 12(6):707-13. PubMed ID: 18935974
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inhibition of soluble CD4 therapy by antibodies to HIV.
    Dis Markers; 1990; 8(2):107-8. PubMed ID: 2387123
    [No Abstract]   [Full Text] [Related]  

  • 40. Protein minimization of the gp120 binding region of human CD4.
    Sharma D; Balamurali MM; Chakraborty K; Kumaran S; Jeganathan S; Rashid U; Ingallinella P; Varadarajan R
    Biochemistry; 2005 Dec; 44(49):16192-202. PubMed ID: 16331979
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.